MedTech Acquisition Corp entered into a merger agreement with TriSalus Life Sciences, Inc., with TriSalus surviving as a wholly owned subsidiary of MTAC, and TriSalus equity holders receiving shares of MTAC common stock. TriSalus presented additional data related to its clinical study at a conference.